Biocross offers a non-genetic, cost effective, and highly reliable test to evaluate the risk to develop late onset Alzheimer’s Disease. The test detects the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
This new test will allow neurologists an easy and fast stratification of patients in clinical trials, a better prescription of drugs, and the application of lifestyle preventive interventions to prevent or delay the development of the disease.
Included in the Export Interest Directory? Yes
Business Needs: Distributor/Agent/Representative, Investor, Licensing Agreements